Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Hancock

Showing results (111-120 of 123) with videos related to

Pageof 13
Sort By:
Plos One|October 4, 2014
Outcome of central nervous system relapses in childhood acute lymphoblastic leukaemia--prospective open cohort analyses of the ALLR3 trialAshish Narayan Masurekar, Catriona A Parker, Milensu Shanyinde, et al.
Journal of Medicinal Chemistry|January 14, 2000
Selective plasma hydrolysis of glucocorticoid gamma-lactones and cyclic carbonates by the enzyme paraoxonase: an ideal plasma inactivation mechanismK Biggadike, R M Angell, C M Burgess, et al.
Journal of Medicinal Chemistry|September 13, 2024
Discovery and Development of Highly Potent and Orally Bioavailable Nonpeptidic α<sub>v</sub>β<sub>6</sub> Integrin InhibitorsPanayiotis A Procopiou, John Barrett, Matthew H J Crawford, et al.
British Journal of Haematology|August 29, 1998
Minimal residual disease status as a predictor of relapse after allogeneic bone marrow transplantation for children with acute lymphoblastic leukaemiaC J Knechtli, N J Goulden, J P Hancock, et al.
Blood|December 3, 1998
Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemiaC J Knechtli, N J Goulden, J P Hancock, et al.
Journal of Medicinal Chemistry|March 9, 2011
The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitisPanayiotis A Procopiou, Christopher Browning, Jennifer M Buckley, et al.
Journal of Medicinal Chemistry|September 15, 2018
Discovery of ( S)-3-(3-(3,5-Dimethyl-1 H-pyrazol-1-yl)phenyl)-4-(( R)-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)pyrrolidin-1-yl)butanoic Acid, a Nonpeptidic αPanayiotis A Procopiou, Niall A Anderson, John Barrett, et al.
Bioorganic & Medicinal Chemistry Letters|February 3, 2007
Oxazolidinones as novel human CCR8 antagonistsJian Jin, Yonghui Wang, Feng Wang, et al.
Journal of Medicinal Chemistry|February 16, 2013
Synthesis and structure-activity relationships of indazole arylsulfonamides as allosteric CC-chemokine receptor 4 (CCR4) antagonistsPanayiotis A Procopiou, John W Barrett, Nicholas P Barton, et al.
Journal of Medicinal Chemistry|June 22, 2026
Discovery of an Orally Available Potent ER Aminopeptidase 1 (ERAP1) Inhibitor That Enhances Antitumor Responses and Limits Inflammatory Autoimmunity <i>In Vivo</i>Christopher P Tinworth, Justyna Wojno-Picon, Michael Adam, et al.
Pageof 13

Showing results (111-120 of 123) with videos related to

Sort By:
Pageof 13
Plos One|October 4, 2014
Outcome of central nervous system relapses in childhood acute lymphoblastic leukaemia--prospective open cohort analyses of the ALLR3 trialAshish Narayan Masurekar, Catriona A Parker, Milensu Shanyinde, et al.
Journal of Medicinal Chemistry|January 14, 2000
Selective plasma hydrolysis of glucocorticoid gamma-lactones and cyclic carbonates by the enzyme paraoxonase: an ideal plasma inactivation mechanismK Biggadike, R M Angell, C M Burgess, et al.
Journal of Medicinal Chemistry|September 13, 2024
Discovery and Development of Highly Potent and Orally Bioavailable Nonpeptidic α<sub>v</sub>β<sub>6</sub> Integrin InhibitorsPanayiotis A Procopiou, John Barrett, Matthew H J Crawford, et al.
British Journal of Haematology|August 29, 1998
Minimal residual disease status as a predictor of relapse after allogeneic bone marrow transplantation for children with acute lymphoblastic leukaemiaC J Knechtli, N J Goulden, J P Hancock, et al.
Blood|December 3, 1998
Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemiaC J Knechtli, N J Goulden, J P Hancock, et al.
Journal of Medicinal Chemistry|March 9, 2011
The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitisPanayiotis A Procopiou, Christopher Browning, Jennifer M Buckley, et al.
Journal of Medicinal Chemistry|September 15, 2018
Discovery of ( S)-3-(3-(3,5-Dimethyl-1 H-pyrazol-1-yl)phenyl)-4-(( R)-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)pyrrolidin-1-yl)butanoic Acid, a Nonpeptidic αPanayiotis A Procopiou, Niall A Anderson, John Barrett, et al.
Bioorganic & Medicinal Chemistry Letters|February 3, 2007
Oxazolidinones as novel human CCR8 antagonistsJian Jin, Yonghui Wang, Feng Wang, et al.
Journal of Medicinal Chemistry|February 16, 2013
Synthesis and structure-activity relationships of indazole arylsulfonamides as allosteric CC-chemokine receptor 4 (CCR4) antagonistsPanayiotis A Procopiou, John W Barrett, Nicholas P Barton, et al.
Journal of Medicinal Chemistry|June 22, 2026
Discovery of an Orally Available Potent ER Aminopeptidase 1 (ERAP1) Inhibitor That Enhances Antitumor Responses and Limits Inflammatory Autoimmunity <i>In Vivo</i>Christopher P Tinworth, Justyna Wojno-Picon, Michael Adam, et al.
Pageof 13